Skip to main content
. 2022 Dec 21;29(1):10–15. doi: 10.5114/pedm.2022.122547

Table II.

Clinical, biochemical and radiological parameters of study sample (n = 35)

Study parameter Value
Age in years (Standard deviation) 5.9 (4.4)
Age at diagnosis (standard deviation) 0.2 (2.9)
Age-wise distribution
< 2 years 5 (14.2%)
2–5 years 11 (31.4%)
5–10 years 13 (37.1%)
> 10 years 6 (17.1)
Sex distribution (M : F) 1.1 : 1 (19/16)
Tanner’s stage
Stage 1 26 (74.2%)
Stage 2 3 (8.5%)
Stage 3 2 (5.7%)
Stage 4 2 (5.7%)
Stage 5 2 (5.7%)
Type of CAH
Salt wasting 22 (62.8%)
Simple virilizing 12 (34.2%)
Non-classical 1 (2.8%)
Median 17 OHP (ng/ml) at presentation (range) 39 ng/ml (0.26-832)
Median 17 OHP (ng/ml) diagnosed by NBS (range) 237.5 ng/ml (29-406)
Hypotensive at presentation 6 (17.1%)
Height Z-score at presentation (percentage short) –0.12 ±2.0 (22%)
Weight Z-score at presentation –0.45 ±1.9
BMI Z-score at presentation (percentage with wasting) –0.43 ±1.6 (22%)
17 OHP (ng/ml) at follow-up (median) 3.52 ng/ml
BP at follow up (percentage hypotensive) 2 (5.7%)
SBP median (mmHg) 104 ±17
DBP median (mmHg) 70 ±11
Height Z-score at follow-up (percentage short) –0.12 ±1.6 (20%)
Salt wasting –0.15 ±1.6 (22.7%)
Simple virilising –0.03 ±1.6 (16.6%)
Weight Z-score at follow-up –0.09 ±1.6
Salt wasting –0.02 ±1.6
Simple virilising –0.16 ±1.6
BMI Z-score at follow-up (percentage overweight and obesity) –0.50 ±1.0 (17.1% and 25%)
Severity of virilization severe
Before 2018
Prader Stage 0 0
Prader Stage 1 1
Prader Stage 2 1
Prader Stage 3 2
Prader Stage 4 3
Prader Stage 5 0
After 2018
Prader Stage 0 1
Prader Stage 1 0
Prader Stage 2 1
Prader Stage 3 4
Prader Stage 4 3
Prader Stage 5 0

CAH – congenital adrenal hyperplasia; 17-OHP – 17-hydroxyprogesterone; NBS – newborn screening; BMI – body mass index; BP – blood pressure; SBP – systolic blood pressure; DBP – diastolic blood pressure